Q-omics provides the consensus-scored SAMD4B profile across patient tissues and cancer cell-line models. SAMD4B expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SAMD4B is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SAMD4B RNA expression shows 20,773 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where SAMD4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAMD4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAMD4B survival associations across molecular data types. SAMD4B RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAMD4B RNA expression–survival associations across cancer types. High SAMD4B expression shows unfavorable associations in ACC, BLCA, MESO and LGG, but favorable associations in SCLC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SAMD4B RNA expression.
This table summarizes SAMD4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SAMD4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAMD4B shows higher tumor expression in HNSC, COAD, KIRC, LIHC, LUAD and LUSC. The HNSC box plot shows higher SAMD4B RNA expression in tumor versus normal tissue (log2 FC = +1.023, t-test p < 0.001).
This table shows molecular features associated with SAMD4B in patient tissues and cancer cell lines. In patient samples, SAMD4B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SAMD4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
